A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands. Novavax on Wednesday said the Food and Drug Administration has put a hold on its application for a combination shot targeting Covid and influenza and a standalone flu vaccine, sending the company's shares down sharply. The biotech company's stock fell nearly 20% on Wednesday. The so-called clinical hold is due to a single rep ...

The most recent trading session ended with Novavax (NVAX) standing at $12.91, reflecting a +1.77% shift from the previouse trading day's closing. The stock exceeded the S&P 500, which registered a loss of 0.21% for the day. On the other hand, the Dow registered a loss of 0.14%, and the technology-centric Nasdaq decreased by 0.05%. Shares of the vaccine maker witnessed a gain of 3.17% over the previous month, beating the performance of the Medical sector with its loss of 3.28% and underperforming the S&P 500 ...

Shares of Novavax (NVAX, Financial), a biotechnology firm specializing in vaccine development, experienced a significant drop of 5.11%. The stock is currently priced at $12.92 with a trading volume of approximately 3.03 million shares, reflecting a turnover rate of 1.89% and a price fluctuation of 6.10%. Recent financial data reveals Novavax achieved a revenue of $415 million, net earnings of $162 million, and earnings per share of $1.09. The company's gross profit stands at $379 million, with a price-to-ea ...

Ruxandra Draghia-Akli, MD, PhD brings more than 20 years of extensive clinical, corporate and global public health expertise to support Novavax's transition to an R&D-focused organization Dr. Draghia-Akli will be integral in strategically evaluating the Company's pipeline and opportunities for its Matrix-M™ adjuvant and protein-based technology platform GAITHERSBURG, Md., Sept. 25, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvan ...

The latest trading session saw Novavax (NVAX) ending at $12.80, denoting a -0.85% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily gain of 0.28%. Meanwhile, the Dow experienced a rise of 0.15%, and the technology-dominated Nasdaq saw an increase of 0.15%. Coming into today, shares of the vaccine maker had gained 7.67% in the past month. In that same time, the Medical sector gained 0.38%, while the S&P 500 gained 2%. The upcoming earnings release of Novavax will b ...

Core Points - Novavax's updated COVID-19 vaccine (2024-2025 Formula) is now available at thousands of locations across the U.S. for individuals aged 12 and older [1][3] - The vaccine is the only protein-based option available this fall and has received Emergency Use Authorization (EUA) from the FDA on August 30, 2024 [3][5] - The vaccine targets the JN.1 variant and has shown cross-reactivity against other lineage viruses [4][12] Availability and Distribution - The updated vaccine is expected to be widely available through agreements with major pharmacy retailers including CVS, Walgreens, and Costco, among others [3][4] - The number of locations stocking the vaccine has more than doubled compared to the previous year, enhancing consumer access [4] Vaccine Composition and Technology - The Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2705) is formulated to target the JN.1 variant and utilizes Novavax's Matrix-M adjuvant to enhance the immune response [12][13] - The vaccine is presented in a pre-filled syringe for convenience and is stored at 2° to 8°C, allowing for the use of existing vaccine supply chains [4][12] Safety and Efficacy - The vaccine is indicated for active immunization against COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older [7] - Contraindications include a known history of severe allergic reactions to any component of the vaccine [8] - Adverse reactions may include injection site pain, fatigue, and muscle pain, among others [11]

Regulators recently approved an updated COVID shot from Novavax. Struggling biotech Novavax (NVAX -0.72%) was a hot buy a few years ago as it was in the midst of developing a vaccine for COVID-19. Ultimately, it did produce an approved vaccine, but it was a bit late and did not end up generating nearly as much in revenue as it could have if it had obtained approval much earlier. And since 2022, a sell-off has ensued, with the stock losing more than 91% of its value. Recently, there's been some renewed excit ...

GAITHERSBURG, Md., Sept. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in two upcoming investor conferences. H.C. Wainwright 26th Annual Global Investment Conference: Fireside Chat Date: Monday, September 9, 2024 Time: 3:30 – 4:00 p.m. Eastern Time (ET) Location: New York City, New York Moderator: Vernon Bernardino, Managing Director, Senior Healthcare Analyst Novavax partici ...

Novavax (NVAX) announced that the FDA granted emergency use authorization (EUA) to an updated version of its protein-based COVID-19 vaccine for individuals aged 12 years and older. Following this nod, Novavax's updated vaccine is the only non-mRNA vaccine option available to people in the United States. Management expects pre-filled syringes of the vaccine to be available across the country. This authorization comes just a week after the agency approved/authorized updated the mRNA-based COVID19 vaccines of ...

Novavax expects pre-filled syringes will be broadly available in thousands of locations across the U.S. Novavax's vaccine is the only protein-based option available in the U.S. for use in individuals aged 12 and older to prevent COVID-19 GAITHERSBURG, Md., Aug. 30, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) has received Emergency Us ...